Grey Street Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Grey Street Capital’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$427K	Buy	+444	New	+$422K	0.06%	324

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Grey Street Capital's REGN Position: Q1 2024 in Review

Grey Street Capital opened a new position in Regeneron Pharmaceuticals (REGN) in Q1 2024: 444 shares worth $427K. The stake represents 0.06% of the portfolio and ranks #324 among its holdings.

1,311 funds tracked by Wall St. Rank hold REGN as of Q1 2024.

Grey Street Capital held 444 shares of Regeneron Pharmaceuticals worth $427K as of Q1 2024.
Regeneron Pharmaceuticals was a new Grey Street Capital position in Q1 2024.
Regeneron Pharmaceuticals made up 0.06% of Grey Street Capital's portfolio in Q1 2024, its #324 holding.
1,311 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2024.

Based on Grey Street Capital's 13F filing for Q1 2024, filed 9 Aug 2024.